PolyPid

🇮🇱Israel

Country: 🇮🇱Israel

Ownership: Public

Established: 2008-01-01

Employees: 62

Market Cap: -

Website: http://www.polypid.com

Introduction: PolyPid Ltd. operates as a phase 3 biopharma company. Its proprietary PLEX technology pairs with medications, enables precise delivery of drugs at effective release rates, over pre-determined durations ranging from several days to months. The firm's product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. The company was founded by Noam Emanuel on February 28, 2008 and is headquartered in Petach Tikva, Israel.

Clinical Trials

D-PLEX 312 - Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection (SHIELD II)

Phase 3

Recruiting

Conditions: Surgical Site Infection
Colon Surgery
Abdominal Surgery
Post-Op Infection

Interventions: Drug: D-PLEX
Other: Standard of Care (SoC)

First Posted Date: 2020-06-02

Last Posted Date: 2024-11-12

Lead Sponsor: PolyPid Ltd.

Target Recruit Count: 624

Registration Number: NCT04411199

Locations: 🇭🇺
Pest Megyei Flór Ferenc Kórház Sebészeti Osztály, Kistarcsa, Hungary
🇺🇸
Augusta Univeristy, Augusta, Georgia, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 65 locations

D-PLEX 311: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection

Phase 3

Completed

Conditions: Surgical Site Infection
Colon Surgery
Post-Op Infection
Abdominal Surgery

Interventions: Other: Standard of Care (SoC)
Drug: D-PLEX

First Posted Date: 2020-01-18

Last Posted Date: 2022-09-29

Lead Sponsor: PolyPid Ltd.

Target Recruit Count: 950

Registration Number: NCT04233424

Locations: 🇺🇸
Shoals Medical Trials, Sheffield, Alabama, United States
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇧🇬
"Multiprofile Hospital for Active Treatment - Haskovo" AD, Haskovo, Bulgaria

and more 56 locations

D-PLEX 310: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection

Phase 2

Completed

Conditions: Colon Surgery
Abdominal Surgery
Post-Op Infection

Interventions: Other: Standard of Care (SoC)
Drug: D_PLEX

First Posted Date: 2018-08-16

Last Posted Date: 2020-05-19

Lead Sponsor: PolyPid Ltd.

Target Recruit Count: 200

Registration Number: NCT03633123

Locations: 🇮🇱
Sheba MC, Tel-Hashomer, Ramat Gan, Israel
🇮🇱
Wolfson MC, Holon, Israel
🇮🇱
Rabin MC, Campus Beilinson, Petach Tikva, Israel

and more 5 locations

D-PLEX 302: Efficacy and Safety of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery

Phase 3

Terminated

Conditions: Surgical Site Infection
Cardiac Surgery
Sternal Infection

Interventions: Drug: D-PLEX
Other: Standard of Care

First Posted Date: 2018-06-15

Last Posted Date: 2022-11-15

Lead Sponsor: PolyPid Ltd.

Target Recruit Count: 2

Registration Number: NCT03558984

Locations: 🇮🇱
Soroka Medical Center, Beer Sheva, Israel
🇺🇸
Memorial Hermann, Houston, Texas, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Safety and Efficacy of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery

Phase 1

Completed

Conditions: Postoperative Wound Infection Superficial Incisional
Postoperative Wound Infection Deep Incisional Surgical Site

Interventions: Drug: D-PLEX
Procedure: Open heart surgery

First Posted Date: 2016-04-07

Last Posted Date: 2019-01-22

Lead Sponsor: PolyPid Ltd.

Target Recruit Count: 80

Registration Number: NCT02731573

Locations: 🇮🇱
Soroka Medical Center, Beer sheva, Israel
🇮🇱
Rambam Medical Center, Haifa, Israel
🇮🇱
Assuta Medical Center, Tel Aviv, Israel

and more 2 locations

BonyPid-500TM Bone Graft Substitute Study

Not Applicable

Completed

Conditions: Peri Implantitis

Interventions: Device: BonyPid 500TM implantation concomitantly to SOC treatment
Other: SOC treatment only

First Posted Date: 2015-08-24

Last Posted Date: 2018-06-26

Lead Sponsor: PolyPid Ltd.

Target Recruit Count: 27

Registration Number: NCT02531100

Locations: 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
🇮🇱
Rambam Health Care Campus, Haifa, Israel

Safety and Performance of BonyPid-1000™ in the Treatment of Gustilo I, II, IIIA and IIIB Tibial Open Fractures

Not Applicable

Completed

Conditions: Open Fractures
Tibial Fractures

Interventions: Device: BonyPid-1000
Other: Standard of Care (SOC) treatment

First Posted Date: 2015-07-07

Last Posted Date: 2020-05-19

Lead Sponsor: PolyPid Ltd.

Target Recruit Count: 51

Registration Number: NCT02491047

Locations: 🇵🇭
De La Salle HSI, Cavite, Philippines
🇵🇭
Philippines General Hospital, Manila City, Philippines
🇵🇭
Philippine Orthopedic Center, Quezon City, Philippines

and more 6 locations

Home Terms & Conditions Privacy Policy